A PYMNTS Company

US/Canada: Valeant Pharmaceuticals cleared for takeover

By  |  April 22, 2013

The waiting period for Valeant Pharmaceuticals International’s acquisition of its indirect, wholly-owned subsidiary Odysseus Acquisition Corp. has formally expired, allowing the company to proceed with the transaction. While the deal remains subject to the Antimonopoly Committee of Ukraine, Valeant is reportedly expecting approval in the near future. While the value of the acquisition was not reports, the sale will be made for $24 per share without interest. The waiting period officially expired at midnight on April 19.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.